Home Companies Catalysts Deep Dives
camizestrant camizestrant PHASE3
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Peak Sales Est$2500M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: Oral SERD
Expert: Selective estrogen receptor degrader that binds ER and promotes its proteasomal degradation.
Everyday: A pill that destroys the estrogen receptor protein in breast cancer cells.
Targets: ["ESR1"]
Programs (1)
IndicationStageKey StudyRegional Status
ER+/HER2- aBCPHASE3SERENA-6[]
Upcoming Catalysts (1)
Camizestrant - HR+ Breast - Ph3 - Topline (SERENA-4) H2 2026
Notes
Oral SERD for HR+ breast cancer. Key NME.
Data from Supabase · Updated 2026-03-24